Prescriptions for semaglutide and tirzepatide among patients with PCOS Between 2021 and 2025, 445,258 patients with PCOS had at least one medical encounter, of whom 90,206 (20.3%) received a semaglutide or tirzepatide prescription during the study period
An exclusive in-license to a foundational technology, covering the exact field and territory the acquirer needs, is a high-value asset
Safety Evaluation and Provider Decision Framework Before starting any GLP-1 medication, patients with ulcerative colitis should undergo thorough evaluation including disease activity assessment, recent colonoscopy findings, current immunosuppressive therapy, and baseline gastrointestinal symptoms
Therapeutic strategies that directly reduce mortality and extend healthspan are therefore urgently needed
While probably not directly caused by supplements, such symptoms always require investigation
It differs from ALCAR, which is often used for cognitive support